10-Q: Profound Medical Corp. Q2 2026 Revenue Surges 62%

Profound Medical Corp. reported a 62% increase in revenue for the first six months of 2026, driven by strong capital equipment sales, while operating expenses decreased.

Summary

• Profound Medical Corp. reported a 62% increase in revenue for the first six months of 2026, reaching $7.82 million compared to $4.83 million in the same period of 2025.
• For the three months ended June 30, 2026, revenue grew 12% to $2.48 million.
• Gross profit increased by 66% for the six-month period to $5.78 million, with a gross margin of 74%.
• Operating expenses decreased by 13% for the six-month period to $24.87 million.
• The company reported a net loss of $16.59 million for the six months ended June 30, 2026, an improvement from a net loss of $26.42 million in the prior year.
• Cash reserves decreased to $38.27 million as of June 30, 2026, from $59.72 million at the end of 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with significant revenue growth and improved gross margins, though the company continues to operate at a net loss.

Positives

• Significant revenue growth of 62% for the first six months of 2026, reaching $7.82 million.
• Revenue for the second quarter of 2026 increased by 12% to $2.48 million.
• Gross profit for the six-month period increased by 66% to $5.78 million, with a gross margin of 74%.
• Operating expenses decreased by 13% for the six-month period to $24.87 million.
• R&D expenses saw a slight decrease of 7% for the three-month period, attributed to the completion of CAPTAIN trial enrollment.
• SG&A expenses decreased by 20% for the six-month period to $13.95 million.
• Net loss improved significantly, decreasing by 37% to $16.59 million for the six-month period.
• The company is in compliance with its financial covenants under the CIBC Credit Agreement.

Negatives

• The company continues to incur substantial net losses, with a loss of $16.59 million for the six months ended June 30, 2026.
• Cash reserves have decreased to $38.27 million from $59.72 million at the end of 2025.
• The company expects expenses to increase due to continued commercialization efforts.
• The company may require additional capital in the future, which could lead to dilution for existing shareholders or increased debt obligations.

Risks

• Future compliance with financial covenants is dependent on achieving certain revenue, EBITDA, and anticipated unrestricted cash levels.
• The company may require additional capital to fund R&D activities and expansion, and there is no assurance that such capital will be obtainable on favorable terms.
• Failure to raise additional funds could require significant curtailment of operations or inability to take advantage of business opportunities.
• The company is subject to risks described in its Annual Report on Form 10-K, with no material changes noted.

Future Outlook

The company expects its existing cash and sales of products and services to fund operating expenses and capital expenditure requirements for at least the next 12 months. Expenses are expected to increase due to continued commercialization of TULSA-PRO and Sonalleve. Additional capital may be required for R&D and expansion.

Management Comments

• The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum.
• TULSA employs real-time MR guidance for pixel-by-pixel precision to preserve prostate disease patients urinary continence and sexual function, while killing the targeted prostate tissue via a precise sound absorption technology that gently heats it to kill temperature (55-57C).
• TULSA is an incision- and radiation-free one-and-done procedure performed in a single session that takes a few hours.
• Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA.
• There is generally no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine.

Industry Context

StockSavvy.ai notes that Profound Medical Corp. operates in the competitive medical device sector, focusing on minimally invasive ablation technologies. The reported revenue growth and improved gross margins align with a trend towards more advanced, less invasive treatments in urology and oncology, though continued net losses highlight the challenges of scaling such technologies.

Comparison to Industry Standards

• The company's revenue growth of 62% for the first six months of 2026 significantly outpaces the typical growth rates for established medical device companies, suggesting strong market adoption for its specific technologies.
• The gross margin of 74% is robust and competitive within the medical device industry, particularly for specialized therapeutic systems.
• The continued net loss, while improving, is not uncommon for commercial-stage medical device companies investing heavily in R&D, clinical trials, and market expansion, such as those in the robotic surgery or advanced imaging fields.
• Competitors in the prostate cancer treatment space include companies offering traditional surgery, radiation therapy, and other minimally invasive techniques, making Profound's incision-free, MRI-guided approach a differentiated offering.

Legal Proceedings

• The company is not currently a party to or aware of any proceedings that are believed to have a material adverse effect on its business, financial condition, or results of operations.

Stakeholder Impact

• Shareholders may experience dilution if additional equity financing is pursued.
• Creditors and lenders (e.g., CIBC) are impacted by the company's financial performance and compliance with loan covenants.
• Patients benefit from the development and availability of advanced, minimally invasive therapeutic systems.
• Employees are subject to the company's ongoing R&D and commercialization efforts, with share-based compensation impacting their potential equity stake.

Next Steps

• Continue commercialization of the TULSA-PRO system in the United States.
• Continue development and commercialization of the TULSA-PRO and Sonalleve systems globally.
• Fund operating expenses and capital expenditure requirements for at least the next 12 months.
• Monitor compliance with financial covenants under the CIBC Credit Agreement.
• Explore additional potential treatment markets for Sonalleve.

Key Dates

Recommendation

The significant revenue growth and improved financial metrics are positive indicators. However, the continued substantial net loss and decrease in cash reserves, coupled with the potential need for future capital raises, warrant a cautious 'hold' rating. Investors should monitor the company's path to profitability and its ability to secure necessary funding.

Keywords

medical device, TULSA-PRO, Sonalleve, MRI-guided ablation, prostate cancer, uterine fibroids, revenue growth, net loss